What do we know now about the number of doses needed for people on immunosuppressant medications to be protected from severe COVID? What about the use of “passive” protection like monoclonal antibodies? Why are negative antibody tests more helpful than positive ones? Why are large agencies like the CDC and FDA not discussing individualized medicine when it comes to vaccine protocols? What’s the next step in researching COVID-19 vaccine protocols for this unique population of patients? Johns Hopkins transplant surgeon Dr. Dorry Segev returns to the podcast to talk with Stephanie Desmon about what we now know and what still needs to be figured out.
